secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2022-06-16T23:59:59+00:00
Accession:  0001193125-22-175284
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Aileron appoints interim CFO; shareholders approve reverse stock split (1:5–1:25)
--------------------------------------------------------------------------------

- Susan L. Drexler appointed interim CFO effective June 16, 2022, via consulting agreement with Danforth Advisors.
- Shareholders approved reverse stock split (1:5 to 1:25) and proportional increase in authorized shares, board to set ratio by Dec 31, 2022.
- Stockholders ratified PwC as independent auditor for fiscal year 2022.
- William McKee and Nolan Sigal re-elected as Class II directors for three-year terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312522175284/0001193125-22-175284-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312522175284/d256872d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-175284

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer